Drug intelligence / Profile preview

GB400

Development stage: Preclinical
Lead developer: Galleon Bio
Modality: Small Molecules
Administration: Topical

Overview

**GB400** is a preclinical topical small-molecule conjugate developed by Galleon Bio for psoriasis, with additional development interest in systemic pruritus and diabetic neuropathy. The product is described as a second-generation triple-agent platform incorporating N-acetylcysteine, gallic acid, and strontium. Galleon Bio characterizes GB400 as having antioxidant, anti-inflammatory, immunomodulatory, and antipruritic activity; however, no specific molecular target or target-binding mechanism has been publicly identified.

Beyond the preview

Go deeper on GB400.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GB400.

Explore the full profile